RT Journal Article
SR Electronic
T1 Population based estimates of comorbidities affecting risk for complications from COVID-19 in the US
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.30.20043919
DO 10.1101/2020.03.30.20043919
A1 Adams, Mary L.
A1 Katz, David L.
A1 Grandpre, Joseph
YR 2020
UL http://medrxiv.org/content/early/2020/04/02/2020.03.30.20043919.abstract
AB We used 2017 Behavioral Risk Factor Surveillance System (BRFSS) data (N=444,649) to estimate the proportion of US adults who report comorbidities that suggest heightened risk of complications from COVID-19. Co-morbidities included cardiovascular disease, chronic obstructive pulmonary disease (COPD), diabetes, asthma, hypertension, and/or cancer other than skin, based on data from China. Overall 45.4% (95% CI 45.1-45.7) of adults reported any of the 6 comorbidities, increasing from 19.8% (19.1-20.4) for ages 18-29 years to 80.7% (79.5-81.8) for ages 80+ years. State rates ranged from 37.3% (36.2-38.5) in Utah to 58.7% (57.0-60.4) in West Virginia. Rates also varied by race/ethnicity, health insurance status, and employment. Excluded were residents of nursing homes or assisted living facilities. Although almost certainly an underestimate of all adults at risk due to these exclusions, these results should help in estimating healthcare needs for adults with COVID-19 complications living in the community.Article Summary Line Overall, 45.4% of US adults were estimated to be at heightened risk of COVID-19 complications due to co-morbidities, increasing from 19.8% for ages 18-29 years to 80.7% for ages 80+ years, with state-to-state variation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementData collection, analysis, and interpretation of data for this study were supported by the Centers for Disease Control and Prevention (CDC) Grant/Cooperative Agreement number 1U58DP006069-01Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOn-line with link provided in paper https://www.cdc.gov/brfss/data_documentation/index.htm